Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Hosted on MSN1d
LNTH: Evergreen Acquisition Promotes Future InnovationLNTH Lantheus to Buy Evergreen Theragnostics Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its second acquisition this ...
Radiopharmaceutical specialist Lantheus Holdings (NASDAQ: LNTH) had some news to report Tuesday morning, but the market ...
Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...
Lantheus (LNTH) announced the appointment of Phuong Khanh Morrow, M.D. to Lantheus’ Board of Directors, effective February 1, 2025. As an ...
Massachusetts-based radiopharmaceutical company Lantheus (Nasdaq: LNTH) has announced a plan to acquire clinical-stage ...
Lantheus Holdings, Inc. (LNTH) stock price is 91.13 and Lantheus Holdings, Inc. (LNTH) 10-day simple moving average is 94.66. Lantheus Holdings, Inc. (LNTH) stock price is 91.13 and ...
Short interest in Lantheus Holdings Inc (NASDAQ:LNTH) increased during the last reporting period, rising from 4.68M to 6.19M. This put 11.76% of the company's publicly available shares short.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback